Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-0189 + rituximab
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GS-0189 + rituximab is a **combination therapy** consisting of GS-0189, a humanized monoclonal antibody targeting signal regulatory protein alpha (SIRPα), and rituximab, a monoclonal antibody targeting CD20. GS-0189 blocks SIRPα to disrupt the CD47-SIRPα "don't eat me" antiphagocytic signal on tumor cells, thereby enhancing macrophage-mediated phagocytosis and antitumor activity. Rituximab targets CD20 on B cells, mediating cell death through direct and immune-mediated mechanisms. Clinical development was focused on relapsed/refractory non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma. The combination was evaluated in a phase 1 study (NCT04502706), but the trial was terminated and clinical development discontinued[1][2][3][5][6][7][8][10].
- Other names
- GS-0189 + rituximab
02
Targets
SIRPA (Signal-regulatory protein alpha)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on GS-0189 + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-0189 + rituximab.